Wave Life Sciences 경영진

경영진 기준 점검 2/4

Wave Life Sciences CEO는 Paul B. Bolno, Dec2013 에 임명되었습니다 의 임기는 12.58 년입니다. 총 연간 보상은 $12.28M, 5.7% 급여 및 94.3% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 €108.30K 가치에 해당하는 회사 주식의 0.01% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 5.6 년과 9.7 년입니다.

핵심 정보

Paul B. Bolno

최고경영자

US$12.3m

총 보수

CEO 급여 비율	5.70%
CEO 재임 기간	12.6yrs
CEO 지분 보유율	0.01%
경영진 평균 재임 기간	5.6yrs
이사회 평균 재임 기간	9.7yrs

최근 경영진 업데이트

Recent updates

CEO 보수 분석

Paul B. Bolno의 보수는 Wave Life Sciences의 수익에 비해 어떻게 변했나요?
날짜	총 보수	급여	회사 수익
Mar 31 2026	n/a	n/a	-US$184m
Dec 31 2025	US$12m	US$700k	-US$204m
Sep 30 2025	n/a	n/a	-US$122m
Jun 30 2025	n/a	n/a	-US$130m
Mar 31 2025	n/a	n/a	-US$112m
Dec 31 2024	US$4m	US$656k	-US$97m
Sep 30 2024	n/a	n/a	-US$143m
Jun 30 2024	n/a	n/a	-US$73m
Mar 31 2024	n/a	n/a	-US$62m
Dec 31 2023	US$4m	US$636k	-US$58m
Sep 30 2023	n/a	n/a	-US$85m
Jun 30 2023	n/a	n/a	-US$131m
Mar 31 2023	n/a	n/a	-US$151m
Dec 31 2022	US$3m	US$618k	-US$162m
Sep 30 2022	n/a	n/a	-US$153m
Jun 30 2022	n/a	n/a	-US$120m
Mar 31 2022	n/a	n/a	-US$118m
Dec 31 2021	US$4m	US$597k	-US$122m
Sep 30 2021	n/a	n/a	-US$116m
Jun 30 2021	n/a	n/a	-US$143m
Mar 31 2021	n/a	n/a	-US$145m
Dec 31 2020	US$1m	US$579k	-US$150m
Sep 30 2020	n/a	n/a	-US$178m
Jun 30 2020	n/a	n/a	-US$196m
Mar 31 2020	n/a	n/a	-US$197m
Dec 31 2019	US$4m	US$579k	-US$194m

보상 대 시장: Paul B.의 총 보수(USD12.28M)는 German 시장에서 비슷한 규모 기업의 평균(USD1.87M)보다 높습니다.

보상과 수익: Paul B.의 보상은 회사가 적자임에도 증가했습니다.

CEO

Paul B. Bolno (52 yo)

12.6yrs

재임 기간

US$12,277,916

보수

Dr. Paul B. Bolno, M.D., MBA, serves as Independent Director since September 2025 at Invivyd, Inc. He is Director of Expression Edits. He served as an Independent Director at SQZ Biotechnologies Company si...

리더십 팀

이름	직위	재임 기간	보수	지분
Paul B. Bolno	President	12.6yrs	US$12.28m	0.010% € 108.3k
Gregory L. Verdine	Founder & Director	no data	US$412.04k	0.13% € 1.4m
Kyle B. Moran	CFO & Principal Accounting Officer	5.6yrs	US$3.75m	0.030% € 313.5k
Chandra Vargeese	Chief Technology Officer	6.2yrs	US$3.40m	0.17% € 1.8m
Christopher Francis	Senior VP of Corporate Development & Head of Emerging Areas	9.5yrs	US$2.47m	0.0023% € 23.9k
Erik Ingelsson	Chief Scientific Officer	2.2yrs	데이터 없음	0.0091% € 95.8k
Kate Rausch	Head of Investor Relations	7.3yrs	데이터 없음	데이터 없음
Linda Rockett	Senior VP & General Counsel	10.2yrs	데이터 없음	데이터 없음
Daryn Lewis	Senior VP & Head of Human Resources	3.5yrs	데이터 없음	데이터 없음
Sridhar Vaddeboina	Senior Vice President of Chemistry	4.7yrs	데이터 없음	데이터 없음
Hsiu-Chiung Yang	Senior Vice President of Translational Medicine	3.5yrs	데이터 없음	데이터 없음
Christopher I. Wright	Chief Medical Officer	1.2yrs	데이터 없음	데이터 없음

5.6yrs

평균 재임 기간

57.5yo

평균 나이

경험이 풍부한 관리: 1U5의 경영진은 노련하고 경험이 풍부합니다(평균 재임 5.6 년).

이사회 구성원

이름	직위	재임 기간	보수	지분
Paul B. Bolno	President	12.3yrs	US$12.28m	0.010% € 108.3k
Gregory L. Verdine	Founder & Director	13yrs	US$412.04k	0.13% € 1.4m
Mark H. Corrigan	Independent Director	6.8yrs	US$437.04k	0% € 0
Christian O. Henry	Independent Chairperson	9.7yrs	US$462.67k	0% € 0
Adrian George Rawcliffe	Independent Director	9.4yrs	US$432.04k	0% € 0
Peter Kolchinsky	Independent Director	11.5yrs	US$412.04k	0.0084% € 88.3k
Ken Takanashi	Independent Director	14yrs	US$412.04k	0.0058% € 61.5k
Heidi L. Wagner	Independent Director	6.8yrs	US$427.04k	0.0084% € 88.3k
Aik Na Tan	Independent Director	5.9yrs	US$784.07k	0% € 0

9.7yrs

평균 재임 기간

58yo

평균 나이

경험이 풍부한 이사회: 1U5의 이사회는 경험이 있음으로 간주됩니다(평균 재임 9.7 년).

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/07/12 04:12
종가	2026/07/10 00:00
수익	2026/03/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Wave Life Sciences Ltd.는 28명의 분석가가 다루고 있습니다. 이 중 16명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Alec Stranahan	BofA Global Research
Madison Wynne El-Saadi	B. Riley Securities, Inc.
Whitney Ijem	Canaccord Genuity

Wave Life Sciences 경영진

경영진 기준 점검 2/4

핵심 정보

최근 경영진 업데이트

Insufficient new directors

Wave Life Sciences Ltd., Annual General Meeting, Aug 05, 2025

Wave Life Sciences Ltd Announces Appointment of Christopher Wright as Chief Medical Officer

Wave Life Sciences Ltd., Annual General Meeting, Aug 06, 2024

Wave Life Sciences Announces Appointment of Erik Ingelsson as Chief Scientific Officer

President recently sold €111k worth of stock

Recent updates

Wave Life Sciences Ltd. Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing

Insufficient new directors

Wave Life Sciences Ltd. to Report Q1, 2026 Results on Apr 28, 2026

Wave Life Sciences Ltd. Announces Positive Interim Phase 1 Data From INLIGHT

Wave Life Sciences Ltd. to Report Q4, 2025 Results on Feb 26, 2026

Wave Life Sciences Ltd. Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency

Wave Life Sciences Ltd. Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss

Wave Life Sciences Ltd. has filed a Follow-on Equity Offering in the amount of $250 million.

Wave Life Sciences Ltd. to Present Preclinical Data Supporting Therapeutic Potential of Wve-007 for Obesity At Obesityweek®? 2025

Wave Life Sciences Ltd. to Report Q3, 2025 Results on Nov 10, 2025

Wave Life Sciences Ltd. Announces Positive Target Engagement Data from INLIGHT Clinical Trial of WVE-007 for Obesity

Wave Life Sciences Ltd. Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency

Wave Life Sciences Ltd. to Report Q2, 2025 Results on Jul 30, 2025

Wave Life Sciences Ltd., Annual General Meeting, Aug 05, 2025

Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007's Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions

Wave Life Sciences Ltd Announces Appointment of Christopher Wright as Chief Medical Officer

Wave Life Sciences Ltd. to Report Q1, 2025 Results on May 08, 2025

Wave Life Sciences Ltd. Announces Positive Data from FORWARD-53 Clinical Trial in DMD Including Significant Functional Benefit and Reversal of Muscle Damage After 48 Weeks of Dosing with WVE-N531

Wave Life Sciences Ltd. to Report Q4, 2024 Results on Mar 04, 2025

Wave Life Sciences Ltd. Announces Initiation of Phase 1 INLIGHT Clinical Trial of WVE-007 in Obesity

Wave Life Sciences Ltd. Announces Submission of First Clinical Trial Application for WVE-007 (siRNA Targeting INHBE) in Obesity

Third quarter 2024 earnings released: US$0.47 loss per share (vs US$0.066 profit in 3Q 2023)

Wave Life Sciences Ltd. has filed a Follow-on Equity Offering in the amount of $250 million.

Wave Life Sciences Ltd. to Report Q3, 2024 Results on Nov 12, 2024

Wave Life Sciences Ltd. Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency

New major risk - Shareholder dilution

Wave Life Sciences Ltd. has completed a Follow-on Equity Offering in the amount of $200.000004 million.

Wave Life Sciences Ltd. has completed a Follow-on Equity Offering in the amount of $131.97401 million.

Wave Life Sciences Ltd. Announces Positive Interim Data from Forward-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping

Wave Life Sciences Receives FDA Rare Pediatric Disease Designation for WVE-N531 for the Treatment of Duchenne Muscular Dystrophy

Second quarter 2024 earnings released: US$0.25 loss per share (vs US$0.20 loss in 2Q 2023)

Wave Life Sciences Ltd. Announces Positive Results from Phase 1b/2a Select-HD Trial with First Clinical Demonstration of Allele-Selective Mutant Huntingtin Lowering in Huntington's Disease

Wave Life Sciences Ltd., Annual General Meeting, Aug 06, 2024

New major risk - Revenue and earnings growth

Wave Life Sciences Announces Appointment of Erik Ingelsson as Chief Scientific Officer

First quarter 2024 earnings released: US$0.24 loss per share (vs US$0.27 loss in 1Q 2023)

Wave Life Sciences Ltd. to Report Q1, 2024 Results on May 09, 2024

Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial of WVE-006 in Individuals with Alpha-1 Antitrypsin Deficiency

Full year 2023 earnings released: US$0.54 loss per share (vs US$2.05 loss in FY 2022)

New major risk - Revenue and earnings growth

Wave Life Sciences Ltd. to Report Q4, 2023 Results on Mar 06, 2024

Wave Life Sciences Announces Initiation of Dosing in Phase 2 FORWARD-53 Trial of WVE-N531 in Duchenne Muscular Dystrophy

Wave Life Sciences Ltd. has completed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Share price stability

Wave Life Sciences Ltd. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Financial position

Third quarter 2023 earnings released: EPS: US$0.071 (vs US$0.41 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Wave Life Sciences Ltd. to Report Q3, 2023 Results on Nov 09, 2023

Wave Life Sciences Ltd. Announces Submission of First Clinical Trial Application for Wve-006

New major risk - Share price stability

Second quarter 2023 earnings released: US$0.20 loss per share (vs US$0.62 loss in 2Q 2022)

Wave Life Sciences Ltd. to Report Q2, 2023 Results on Aug 03, 2023

Wave Life Sciences Announces Topline Results from Phase 1B/2A Focus-C9 Study of WVE-004 for C9orf72-Associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

President recently sold €111k worth of stock

Wave Life Sciences Provides Positive Update on Proof-Of-Concept Study for Wve-N531 in Duchenne Muscular Dystrophy

Wave Life Sciences Ltd. announced that it expects to receive $50 million in funding from GSK plc

Insufficient new directors

Insufficient new directors

Insufficient new directors

Wave Life Sciences Ltd. Announces Management Changes

Wave Life Sciences Announces Positive Update from Phase 1b/2a SELECT-HD Trial with Initial Results Indicating Allele-Selective Target Engagement with WVE-003 in Huntington’s Disease

Wave Life Sciences Ltd., Annual General Meeting, Aug 09, 2022

Wave Life Sciences Ltd.(NasdaqGM:WVE) dropped from Russell 2000 Dynamic Index

Wave Life Sciences Ltd. Announces First Clinical Data from Ongoing Focus-C9 Trial of Wve-004 for C9-Als and C9-Ftd

Wave Life Sciences Announces Publication of Foundational Preclinical Data Supporting Development of WVE-004 for C9orf72-associated ALS and FTD

Wave Life Sciences Ltd. Announces Positive Update to Ongoing Phase 1b/2a FOCUS-C9 Study by Potent, Durable Reductions of Poly(GP) with Low, Single Doses of WVE-004

Wave Life Sciences Ltd. Announces Nature Biotechnology Publication Highlighting First RNA Base Editing in Non-Human Primates Using an Endogenous Enzyme

Full year 2021 earnings: EPS in line with expectations, revenues disappoint